Pulmonary Fibrosis Awareness Month may be coming to a close, but it's important to keep the momentum going, columnist Sam Kirton says.

Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...

Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...

A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...

A new statistical technique developed by a researcher at the Texas A&M University School of Public Health and colleagues ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...

Desaturation during the 6-minute walk test is a significant predictive factor for mortality in patients with idiopathic pulmonary fibrosis.

This blog describes a typical ILD patient journey from the initial diagnosis through its long-term management to end-of-life ...

Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic ...

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...